Maxpro Capital Acquisition (JMAC) Competitors $6.56 +0.05 (+0.74%) As of 06/30/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock JMAC vs. ZYBT, HUMA, AARD, AMRN, TERN, AURA, HRTX, PRTA, SNDL, and ATXSShould you be buying Maxpro Capital Acquisition stock or one of its competitors? The main competitors of Maxpro Capital Acquisition include Zhengye Biotechnology (ZYBT), Humacyte (HUMA), Aardvark Therapeutics (AARD), Amarin (AMRN), Terns Pharmaceuticals (TERN), Aura Biosciences (AURA), Heron Therapeutics (HRTX), Prothena (PRTA), SNDL (SNDL), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical products" industry. Maxpro Capital Acquisition vs. Its Competitors Zhengye Biotechnology Humacyte Aardvark Therapeutics Amarin Terns Pharmaceuticals Aura Biosciences Heron Therapeutics Prothena SNDL Astria Therapeutics Maxpro Capital Acquisition (NASDAQ:JMAC) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings. Do insiders and institutionals hold more shares of JMAC or ZYBT? 73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. 19.3% of Maxpro Capital Acquisition shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media favor JMAC or ZYBT? In the previous week, Zhengye Biotechnology had 5 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 5 mentions for Zhengye Biotechnology and 0 mentions for Maxpro Capital Acquisition. Zhengye Biotechnology's average media sentiment score of 0.64 beat Maxpro Capital Acquisition's score of 0.00 indicating that Zhengye Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment Maxpro Capital Acquisition Neutral Zhengye Biotechnology Positive Is JMAC or ZYBT more profitable? Company Net Margins Return on Equity Return on Assets Maxpro Capital AcquisitionN/A N/A N/A Zhengye Biotechnology N/A N/A N/A Which has preferable earnings and valuation, JMAC or ZYBT? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaxpro Capital AcquisitionN/AN/AN/AN/AN/AZhengye BiotechnologyN/AN/AN/AN/AN/A SummaryMaxpro Capital Acquisition and Zhengye Biotechnology tied by winning 2 of the 4 factors compared between the two stocks. Get Maxpro Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JMAC vs. The Competition Export to ExcelMetricMaxpro Capital AcquisitionHolding Offices IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$88.06M$175.20M$2.21B$8.94BDividend YieldN/A5.41%2.62%4.12%P/E RatioN/A2.4722.8619.74Price / SalesN/A460.2251.52109.12Price / CashN/A74.78N/A57.06Price / BookN/A6.81105.725.37Net IncomeN/A$3.67M-$241.20M$248.34M7 Day Performance-1.15%-0.16%0.55%1.67%1 Month Performance7.51%2.32%2.91%4.56%1 Year Performance3,022.86%73.41%22.50%18.42% Maxpro Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JMACMaxpro Capital AcquisitionN/A$6.56+0.7%N/A+3,009.5%$88.06MN/A0.002,021ZYBTZhengye BiotechnologyN/A$7.88+4.5%N/AN/A$355.63MN/A0.00278News CoverageLockup ExpirationHUMAHumacyte2.6607 of 5 stars$2.19-1.8%$11.71+434.9%-57.5%$345.92M$1.57M-3.17150AARDAardvark TherapeuticsN/A$15.38-2.4%$31.25+103.2%N/A$341.93MN/A0.0018News CoverageAnalyst ForecastAnalyst RevisionAMRNAmarin0.7374 of 5 stars$16.19+1.0%$12.00-25.9%+22.5%$332.04M$228.61M-4.45360High Trading VolumeTERNTerns Pharmaceuticals4.3529 of 5 stars$4.06+7.1%$15.63+284.9%-43.8%$331.01MN/A-3.7240Positive NewsGap UpAURAAura Biosciences2.3614 of 5 stars$6.57+0.3%$22.00+234.9%-15.1%$329.26MN/A-3.4650Positive NewsHRTXHeron Therapeutics4.0189 of 5 stars$2.15flat$5.00+132.6%-37.5%$328.01M$144.29M-35.83300News CoveragePRTAProthena3.1859 of 5 stars$5.99-1.3%$31.50+425.9%-69.4%$326.73M$135.16M-2.88130SNDLSNDL3.808 of 5 stars$1.22-1.6%$3.63+197.1%-36.5%$325.84M$671.81M-4.212,516Positive NewsATXSAstria Therapeutics1.8253 of 5 stars$5.65-1.9%$30.00+431.0%-41.3%$325.06MN/A-3.0230 Related Companies and Tools Related Companies ZYBT Competitors HUMA Competitors AARD Competitors AMRN Competitors TERN Competitors AURA Competitors HRTX Competitors PRTA Competitors SNDL Competitors ATXS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JMAC) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maxpro Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maxpro Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
